Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …

Glioblastoma (GBM) is the most malignant CNS tumor with a highest incidence rate, and
most patients would undergo a recurrence. Recurrent GBM (rGBM) shows an increasing …

We previously showed that chimeric antigen receptor (CAR) T-cell therapy targeting
epidermal growth factor receptor variant III (EGFRvIII) produces upregulation of programmed …

Despite significant advances in our knowledge regarding the genetics and molecular
biology of gliomas over the past two decades and hundreds of clinical trials, no effective …

Background Glioblastoma (GBM), a highly immunosuppressive and often fatal primary brain
tumor, lacks effective treatment options. GBMs contain a subpopulation of GBM stem-like …

Simple Summary Glioblastoma is a highly aggressive tumor, and despite standard-of-care
therapy, tumor recurrence is inevitable. Recurrent glioblastoma (rGBM) remains a challenge …

Background Glioma is the most common primary malignant tumor in the brain, and even with
standard treatments including surgical resection, radiotherapy, and chemotherapy, the long …

Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been
recently approved by FDA, driven by basket trials that have demonstrated their efficacy and …

HSV G207, a double-stranded, DNA virus, and the polio: rhinovirus chimera, PVSRIPO, a
single positive-strand RNA virus, are viral immunotherapies being used to treat pediatric …

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease
characterized by a spatially heterogeneous tumor microenvironment. Within the PDA …